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Abstract: The selective estrogen receptor (ER) modulator tamoxifen (TAM) has become the standard
therapy for the treatment of ER+ breast cancer patients. Despite the obvious benefits of TAM,
a proportion of patients acquire resistance to treatment, and this is a significant clinical problem.
Consequently, the identification of possible mechanisms involved in TAM-resistance should help
the development of new therapeutic targets. In this study, we present in vitro data using a panel
of different breast cancer cell lines and demonstrate the modulatory effect of TAM on cellular
proliferation and expression of Hedgehog signaling components, including the terminal effector
of the pathway, the transcription factor GLI1. A variable pattern of expression following TAM
administration was observed, reflecting the distinctive properties of the ER+ and ER´ cell lines
analyzed. Remarkably, the TAM-induced increase in the proliferation of the ER+ ZR-75-1 and BT474
cells parallels a sustained upregulation of GLI1 expression and its translocation to the nucleus.
These findings, implicating a TAM-GLI1 signaling cross-talk, could ultimately be exploited not
only as a means for novel prognostication markers but also in efforts to effectively target breast
cancer subtypes.
Keywords: GLI1; TAM resistance; breast cancer; Hedgehog signaling; cellular proliferation
1. Introduction
Aberrant activation of the Hedgehog (HH) signaling pathway has been implicated in several
cancers including breast cancer [1,2]. HH signal transduction initiates by the ligand Sonic Hedgehog
(SHH) binding to its receptor Patched (PTCH), which acts, in it unliganded form, as an inhibitor of the
activity of the transmembrane co-receptor Smoothened (SMO). Activated SMO releases GLI proteins
(GLIoma-associated oncogene) from cytoplasmic sequestration, allowing the translocation of these
zinc-finger transcription factors to the nucleus, where the transcriptional programs in response to
pathway activation are executed [3,4]. Expression of GLI1, one of the three GLI factors in mammals
and its translocation to the nucleus, are considered valuable markers of HH pathway activation [5].
Three isoforms of GLI1 with variable expression patterns are known: full-length GLI1 [6], N-terminal
deletion variant (GLI1-∆N) identified by Shimokawa et al. (2008) [7] and truncated GLI1 (tGLI1)
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identified by Lo et al. (2009) [8]. Moreover, in 2012 studies by Ramaswamy et al. [1,9] have demonstrated
that GLI1 is abnormally expressed in breast cancer tissues and cells, and this was associated with
tamoxifen-resistance of the breast cancer cells.
Tamoxifen (TAM) is a selective estrogen receptor (ER) modulator, considered to be the first targeted
cancer therapy. TAM is the most commonly used drug in routine clinical practice and represents
the “gold standard” treatment for ER+ breast tumors [10–12]. The ER is expressed in 60%–70% of
breast tumors; therefore, these are candidates for endocrine therapy. However, patients with similar
prognostic factors at diagnosis can vary substantially in their treatment response, develop resistance
and eventually die [12].
Identification of genes and genetic pathways responsive to TAM could provide the necessary
framework for understanding the complex effects of this drug on target cells. This may allow
a rationalization, at least in part, of the development of cellular resistance to TAM treatment.
Additionally, a better understanding of the mechanisms involved in TAM resistance would help to
identify novel molecular targets for treatment therapies and develop more accurate clinicopathological
prognostic factors.
Here, we present in vitro data using a number of different breast cancer cell lines, demonstrating
the modulatory effect of TAM on cellular proliferation and expression of HH signaling components,
in particular GLI1. These findings reveal that GLI1 activation can be implicated in the growth and
progression of breast cancer; however, the precise mechanism by which GL11 contributes to TAM
resistance remains unclear.
2. Results
2.1. Proliferation Assays
TAM treatment significantly inhibited cell proliferation in MCF7 (ER+/HER2´) cells at 24, 48,
and 96 h (Figure 1A), while in T47D (ER+/HER2´) cells, the inhibition of proliferation was not as
pronounced, reaching significance only at 24 and 48 h (Figure 1B). In contrast to MCF7 and T47D cells,
TAM induced a significant increase in the proliferation of ZR-75-1 (ER+/HER2´) cells at 24 h and 96 h
after treatment (Figure 1C). Similar results in ZR-75-1 cells were also observed in BT474 (ER+/HER2+)
cells: TAM induced a significant increase in the proliferation after 24 and 96 h of treatment (Figure 2A).
Finally, in the ER-/HER2+ cell lines (Figure 2), the TAM effect was variable at different time points.
In SKBR3 cells, TAM addition increased cellular proliferation at 96 h (Figure 2B), whereas, in JIMT-1
cells, TAM increased proliferation at 24 and 48 h (Figure 2C).
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Figure 1. Effects of 1 μM TAM treatment for 24 h, 48 h, and 96 h on the proliferation of 
ER+/HER2-breast cancer cells. (A) MCF7; (B) T47D and (C) ZR-75-1. Error bars represent mean 
standard deviation of 16 separate experiments. Significant differences in treated versus untreated 
samples are indicated by the p values, ** p < 0.01. 
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and ER-/HER2+ (B,C) breast cancer cells. (A) BT474; (B) SKBR3 and (C) JIMT-1. Error bars represent 
mean standard deviation of 16 separate experiments. Significant differences in treated versus 
untreated samples are indicated by the p values, * p < 0.05, ** p < 0.01. 
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and total GLI1. However, at 48 and 96 h, there was a reversal of GLI1 expression, with this 
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ZR-75-1 cells also had no detectable levels of SHH. However, in contrast to T47D and MCF7 
cells, there was a sustained increase in GLI1 expression at 24, 48, and 96 h of TAM treatment, and 
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BT474 cells were characterized by an increase in the expression of all genes tested at 24 h.  
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24 h. In JIMT-1 cells, GLI1 expression was reduced at 48 h, but re-appeared at 96 h. These cells were 
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In SKBR3 cells, a particularly pronounced reduction of GLI1 expression at 96 h was observed  
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In conclusion, our data on the mRNA expression indicate that the most sustained activation of 
GLI1 is seen with the ZR-75-1 cells, and the most sustained activation of SMO and SHH with the 
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Figure 2. Effects of 1 µM TAM treatment for 24, 48, and 96 h on the proliferation of ER+/HER2+ (A)
and ER-/HER2+ (B,C) breast cancer cells. (A) BT474; (B) SKBR3 and (C) JIMT-1. Error bars represent
mean standard deviation of 16 separate experiments. Significant differences in treated versus untreated
samples are indicated by the p values, * p < 0.05, ** p < 0.01.
2.2. qRT–PCR Assays, GLI1 Variants, SMO and SHH Expression
TAM treatment of MCF7 cells for 24 h inhibited the mRNA expression of full-length GLI1,
GLI1-∆N and SHH, while SMO expression was increased (Figure 3A). At 48 h, full-length GLI1
remained downregulated, in contrast to GLI1-∆N, which became upregulated. SMO also changed
its pattern of expression and was downregulated. At 96 h, a tendency of increased expression in
all genes tested was observed, which reached statistical significance for GLI1-∆N, total GLI1, and
SHH (Figure 3A).
In T47D cells, no detectable expression of SHH was observed. Moreover, and in contrast to MCF7
cells, the expression levels of GLI1 were increased at 24 h, reaching significance for GLI1-∆N and total
GLI1. However, at 48 and 96 h, there was a reversal of GLI1 expression, with this downregulation
being most pronounced for full-length GLI1. SMO expression was significantly increased at all three
time points (Figure 3B).
ZR-75-1 cells also had no det ctable levels of SHH. However, in contrast to 47D and MCF7 cells,
there a sustained increase in GLI1 expression t 24, 48, and 96 h of TAM treatment, and this was
particularly evident for full- ength GLI1 nd total GLI1. SMO expression did not change at 24 and 48 h
but significantly incr ased t 96 h (Figure 3C).
BT474 c lls ere characterized by an increase in the xpression of all gen s t sted at 24 h. At 48 h,
there was a somewh t r duced increase; however, at 96 , the observ d increase r ach d statistically
significance for all genes. It is worth n ting the major i crease in SHH expression at 96 h, with this
high upregulation observed only in this cell line (Figure 4A).
JIMT-1 and SKBR3 cells demonstrated increased expression of full-length GLI1 and GLI1-∆N at
24 h. In JIMT-1 cells, GLI1 expression was reduced at 48 h, but re-appeared at 96 h. These cells were also
characterized by increased expression of SMO at 24 and 48 h, and of SHH at 96 h (Figure 4B). In SKBR3
cells, a particularly pronounced reduction of GLI1 expression at 96 h was observed (Figure 4C).
In conclusion, our data on the mRNA expression indicate that the most sustained activation of
GLI1 is seen with the ZR-75-1 cells, and the most sustained activation of SMO and SHH with the
BT474 cells.
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2.3. Immunohistochemistry Assays (IHC), Protein Expression of GLI1 in Nucleus and Cytoplasm
As summarized in Table 1, the GLI1 protein expression detected by immunohistochemistry was
variable among the different cell lines analyzed. All untreated cell lines, except T47D and SKBR3 cells,
were negative for GLI1 expression (Figure 5).
Table 1. Immunohistochemical expression analysis of GLI1 protein in breast cancer cell lines without
(Control) or following 1 µM TAM treatment. Quantification and assessment of positivity were
performed as described in Materials and Methods.
Cell Line Control TAM 24 h TAM 48 h TAM 96 h
MCF7 Negative Positive(Nucleus and Cytoplasm)
Positive
(Nucleus and Cytoplasm)
Positive
(Nucleus and Cytoplasm)
T47D Positive Positive +(Nucleus and Cytoplasm) Negative Negative
ZR-75-1 Negative Positive (Nucleus) Positive (Nucleus) Positive (Nucleus)
BT474 Negative Positive (Nucleus) Positive (Nucleus) Positive (Nucleus)
SKBR3 Positive Positive +(Nucleus and Cytoplasm)
Positive +
(Nucleus and Cytoplasm)
Positive +
(Nucleus and Cytoplasm)
JIMT-1 Negative Negative Negative Positive +(Nucleus and Cytoplasm)
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Figure 5. Immunohistochemical expression analysis of GLI1 protein in breast cancer cell lines
without (A,C,E) or following 1 µM TAM treatment for 96 h (B,D,F). Representative pictures for GLI1
immunostaining showing negative expression in untreated MCF7 cells (A); positive expression in
the nucleus and cytoplasm of MCF7 cells after TAM treatment (B); negative expression in untreated
ZR-75-1 cells (C); positive expression in the nucleus of ZR-75-1 cells after TAM treatment (D); positive
expression in untreated SKBR3 cells (E) and increased positive expression in the nucleus and cytoplasm
of SKBR3 cells after TAM treatment (F). Scale bars: 10 µm.
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Interestingly, BT474 and ZR-75-1 cells were the only ones that had a similar pattern of GLI1
expression. In these cells, GLI1 expression was clearly detectable in the nucleus following 24, 48, and
96 h of TAM treatment (Figure 5).
In MCF7 and SKBR3 cells lines administration of TAM resulted in cytoplasmic and nuclear signals
at all three time points (Figure 5).
In T47D cells GLI1 expression was increased at 24 h. However, this was not sustained, as no
signals were observed at 48 and 96 h.
In JIMT-1 cells no GLI1 expression was detected in untreated or after 24 and 48 h of TAM
administration. Nuclear and cytoplasmic signals were, however, observed at 96 h.
In conclusion, the cells that most clearly show a nuclear translocation of GLI1, an event
characterizing activation of Hedgehog signaling, are ZR-75-1 and BT474, the same cells that exhibited
the most sustained increases in the mRNA expression of Hedgehog signaling components.
3. Discussion
In this study, the impact of TAM administration on breast cancer cell lines was investigated.
Specifically, the role of canonical, SMO-/SHH-dependent HH signaling [13,14] and non-canonical,
SMO-/SHH-independent HH signaling [15,16] was addressed, as this pathway has been linked to
tumorigenesis including breast cancer [17–19]. Additionally, the best-known marker of HH signaling
activation, the transcription factor GLI1, was interrogated by expression analysis of full length GLI1
and the GLI1-∆N variant. Expression of the tGLI1 variant was too low for accurate determinations.
Our results show that cell lines that express nuclear GLI1 staining after TAM treatment exhibit an
increase in cell proliferation compared to control, GLI1 negative cells. These findings could indicate
that the HH signaling pathway is an alternative growth promoting mechanism that can be activated
by TAM in breast cancer cells. In fact, it has recently been reported that activation of this pathway
facilitates tumor growth and progression, supporting an association of HH signaling with increased
risk of metastasis and breast cancer-specific death [20]. In this context, it is worth mentioning that
the increased risk of breast cancer by vitamin D deficiency may be, at least partly, mediated via HH
signaling, since vitamin D acts as an antagonist of this signaling pathway [21,22].
Here, the detailed analysis of breast cancer cells provides evidence that TAM treatment reduces
the proliferation of the ER+/HER2´ cell lines MCF7 and T47D. In MCF7 cells, there is a tendency
towards a reduction in the mRNA expression of GLI1 and SHH at 24 h, but at 96 h an increased
expression was observed. The immunohistochemical data on GLI1 are in-line with the increased
mRNA expression at 96 h. T47D cells express no SHH, with SMO and GLI1 expression increasing at
24 h, then GLI1 expression drops at 48 and 96 h, which is indicative of a strong correlation with the
immunohistochemical data.
The ER+/HER2´ ZR-75-1 and the ER+/HER2+ BT474 cell lines show similar proliferation
patterns, namely, an increase following TAM administration, in addition to comparable mRNA and
protein expression. Significantly, in both cell lines the immunohistochemical data demonstrate a
TAM-dependent expression of GLI1 in the nucleus. Compared to MCF7 and T47D these two cell lines
have a more aggressive profile, and this is in-line with the 2012 report by Li et al. [9], where nuclear
GLI1 expression was correlated with unfavorable prognosis in breast cancer.
Interestingly, previous studies in breast cancer have demonstrated that nuclear staining of GLI1
in cancer cells is associated with aggressive tumor characteristics (i.e., tumor stage and lymph node
status) [18], early recurrence, and poor prognosis [23,24]. In addition, our results could be indicative
not only of an aggressive cellular state following GLI1 nuclear translocation after TAM addition, but
also may have implications on the possible role of GLI1 in TAM resistance therapy.
In the ER´/HER+ SKBR3 cell line, the immunohistochemical data show an increase in the
expression of GLI1 following TAM treatment, with this correlating to the mRNA expression only at 24 h.
The cellular proliferation does not change until 96 h, where TAM elicits an increase. Interestingly, at
this time-point, a pronounced reduction of GLI1 mRNA expression is observed. The other ER´/HER+
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cell line, JIMT-1, also increased its proliferation by TAM, but at 24 and 48 h. A correlation of higher
GLI1 mRNA expression and protein detection by immunohistochemistry was observed at 96 h of
TAM treatment.
Although the SKBR3 cell line is negative for ER, this expresses the novel functional estrogen
transmembrane receptor G protein-coupled receptor 30 (GPR30) [25]. Consequently, the observed
effect of TAM on HH signaling pathway could be attributed to this receptor. Biological effects mediated
by GPR30 are maintained when classic ERs are absent or blocked [26]. Furthermore, activation of
GPR30 signaling in response to TAM and a subsequent increase in cell proliferation in breast cancer
cells have also been observed [27–29].
In conclusion, we find that the TAM-dependent increase in the proliferation of the ER+ ZR-75-1
and BT474 cells is in-line with increased GLI1 expression in the nucleus. In the ER´ SKBR3 and JIMT-1
cell lines, the observed pattern is different. Increased proliferation appears to relate with decreased
GLI1 expression, as assessed by combining immunohistochemical and mRNA detection. For the ER+
MCF7 and T47D cells, there is no consistent correlation of GLI1 expression and proliferation changes.
Worth noting is the lack of detectable SHH expression in ZR-75-1 and T47D cells, with this observation
implicating non-canonical HH signaling in these two cellular settings.
Although the MCF7 cell line is the most studied in the determination of the gene expression
profiles in response to treatment with TAM [30,31], the variable pattern of expression of the
TAM-regulated genes examined in our study, both in ER+ and ER´ cells, is likely to reflect the
distinctive properties of these cells. It is therefore conceivable that these findings could, ultimately,
be exploited not only to identify the response of various breast cancer cell types to TAM, but also to
examine whether GLI1 expression may serve as marker of TAM sensitivity and/or resistance.
Overall, our findings suggest that GLI1 may represent a new important prognostic marker in
breast cancer, thereby supporting the use of combined therapies involving HH pathway inhibitors and
endocrine treatment in breast cancer. It should also be mentioned that therapeutic targeting of HH
signaling using inhibitors acting on SMO has resulted in limited success, due to the development of
resistance. However, the current efforts to use inhibitors that act further downstream of the pathway,
at the level of the GLI factors, are promising, as these would also block non-canonical signaling [32].
4. Materials and Methods
4.1. Cell Lines
The human breast cancer cell lines MCF7, T47D, ZR-75-1 (ER+/HER2´), BT474 (ER+/HER2+),
SKBR3 and JIMT-1 (ER´/HER2+) were obtained from the American Type Culture Collection (ATCC,
Manassas, VA, USA). The MCF7, T47D, ZR-75-1, SKBR3 and JIMT-1 cell lines were cultured in an
RPMI 1640 medium (Sigma, St. Louis, MO, USA), while the BT474 cell line was cultured in a DMEM
medium (Sigma). All culture media were supplemented with 10% fetal bovine serum (FBS) (Sigma), an
antibiotic-antimycotic solution (1ˆ) (Sigma), and L-glutamine (2 mM) (Invitrogen GmbH, Karslruhe,
Germany). The cultures were maintained in an incubator at 37 ˝C under 5% CO2.
4.2. Treatment of the Cell Lines with TAM
In order to remove endogenous serum steroids and eliminate the weak estrogen agonistic activity
of phenol red, 48 h prior to the addition of TAM (T5648, Sigma), cells were washed with 5 mL of
phosphate buffered saline (PBS), and were then switched to phenol red-free RPMI 1640 (Sigma)
containing 10% charcoal-stripped fetal bovine serum (FBS) (Sigma). TAM was dissolved in absolute
ethanol, and diluted in the media at 1 µM, and was then added to the culture medium for 24, 48, and
96 h. Cells without TAM treatment were used as controls.
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4.3. Proliferation Assays
Cells were seeded at a density of 2.5–5 ˆ 103 cells per 100 µL of phenol red-free medium in a
96-well multi-well plate. After 24 h, cells were treated with 1 µM TAM for 24, 48, and 96 h; controls
were cells without TAM treatment. At the end of each treatment, cell viability was assessed using
the cell proliferation ELISA kit, BrdU (Roche Diagnostics Deutschland GmbH, Mannheim, Germany).
Measurements of absorbance were performed using a MultiSkan Bichromatic reader (Labsystems,
Helsinki, Finland) against a background control as blank. Experiments were performed in 16 replicates
and expressed as means ˘ SD.
4.4. RNA Isolation
RNA from control and treated cells was prepared with the RNeasy kit (Qiagen, Hamburg,
Germany) followed by verification of the purity and integrity using the ratio of absorbance at 260 nm
and 280 nm. cDNA synthesis was carried out with Fermentas First Strand cDNA Synthesis Kit
for RT-PCR.
4.5. Real-Time PCR
Real-time PCR was carried out with Roche Enzyme Fast start Universal SYBR Green Master
ROX on a 7500 fast real-time PCR system (Applied Biosystems, Foster, CA, USA) and LightCycler®
96 System (Roche Diagnostics GmbH, Mannheim, Germany) with primers designed to detect
full-length GLI1 and GLI1-∆N variant, total GLI1, SHH, and SMO. The housekeeping gene
TBP was used as an internal control based on the least variation of Ct values in the samples
analyzed. Quantification of the relative expression of target genes was performed using the ∆∆Ct
method (fold difference 2´∆∆Ct). The following PCR primers were used: TBP-E3 (exon 3) forward
51-GCCAGCTTCGGAGAGTTCTGGGATT and E4 reverse 51-CGGGCACGAAGTGCAATGGTCTTTA;
full-length GLI1-E3 forward 51-CCACAGTTATGGGCCAGCCAGAGAG, GLI1-∆N-E1/4 forward
51-GCGCCCAGACAGAGGCCCACT and E4 reverse for both GLI1 variants 51-GGCATCC
GACAGAGGTGAGATGGAC; total GLI1-E11 forward 51-CAGCTACATCAACTCCGGCCAATAGGG
and E12 reverse 51-TGCTGCGGCGTTCAAGAGAGA CTG; SMO-E11 forward 51-TTTCT
GTCACCCCTGTGGCAACTCC and E12 reverse 51-CGGGCACACCTCCTTCTTCCTCTTC;
SHH-E1 forward 51-GATGAAGAAAACACCGGAGCGGACA and E2 reverse 51-TCCTCTGAG
TGGTGGCCATCTTCGT.
4.6. Immunohistochemistry Assays (IHC)
Immunohistochemistry detection for GLI1 was carried out on Formalin-Fixed Paraffin Embedded
(FFPE) cell blocks from each cell line (MCF7, T47D, ZR-75-1, BT474, SKBR3 and JIMT-1) with or without
1 µM TAM for 24, 48, and 96 h. At the indicated time points, cells were fixed in formalin, included in
paraffin, and IHC analyses were performed using the rabbit polyclonal primary antibody GLI1 (1:600
dilution; Novus, CO, USA). GLI1 expression was evaluated by determining the percentage of cells
exhibiting immunoreaction. Cells sections in which >10% of cells were stained were considered to be
positive. GLI1 immunoreactivity was compared in control versus treated cell lines. Immunostaining
evaluation was performed independently by three blinded investigators. Positive values given as
Positive+ were used to indicate a higher percentage of cells expressing GLI1 after the addition of TAM
compared to control.
4.7. Statistical Analysis
The Student’s t-test was performed to compare cell proliferation and relative expression from
treated and untreated cell lines. p values less than 0.05 were considered significant (* p < 0.05,
** p < 0.01).
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